Product Description
MK-0359 is a potent and selective, oral PDE4 inhibitor that has a competitive and reversible mode of interaction. (Sourced from: https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=clinical&ligandId=9852)
Mechanisms of Action: PDE4 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: Eastern America
Company CEO: Robert M. Davis
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Arthritis, Rheumatoid|Asthma|Chronic Obstructive Pulmonary Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00482417 |
NCT00482417 | P2 |
Completed |
Arthritis, Rheumatoid |
2003-05-01 |
2022-05-04 |
Treatments |
|
NCT00482898 |
MK0359-013 | P2 |
Completed |
Asthma |
2003-04-01 |
2022-05-04 |
Treatments |
|
NCT00482235 |
NCT00482235 | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
2003-04-01 |
2022-05-04 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|